Company intelligence / Profile preview

Nanohale AG

Planegg-Martinsried, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

Formycon (formerly Scil Technology) has two biosimilars on the market (FYB201/ranibizumab and FYB202/ustekinumab), with FYB203/aflibercept approved by FDA, EMA, and MHRA. The company achieved a key preclinical milestone with FYB208 (dupilumab biosimilar), demonstrating high analytical comparability to the reference drug and supporting streamlined clinical development.[2]

Therapeutic areas: OtherDermatologyRheumatologyPulmonologyOphthalmology
Modalities: Monoclonal antibodyBiosimilarRecombinant proteinProtein formulation
Industry: Biotech

Partnerships

Medtronic (tissue regeneration collaboration)Sanofi (cartilage regeneration collaboration)

Beyond the preview

Go deeper on Nanohale AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanohale AG.

Explore the full profile